A call for a public inquiry into the damaging effects of diethylstilbestrol (DES) is gaining momentum, shining a light on a scandal of regulatory failure and transgenerational harm.
Story Highlights
- DES victims demand a public inquiry into long-term health impacts.
- The drug, initially prescribed to prevent miscarriages, is linked to cancer.
- Advocacy groups highlight a lack of accountability as a regulatory failure.
- Ongoing calls for recognition, compensation, and health monitoring.
Diethylstilbestrol (DES): A Legacy of Harm
Diethylstilbestrol (DES) was prescribed to millions of pregnant women from the 1940s to the 1970s, despite evidence emerging as early as 1953 that it did not prevent miscarriages. In 1971, studies linked DES to an increased risk of rare cancers and reproductive issues in children exposed in utero, leading to the drug’s eventual phase-out. Victims now demand a public inquiry into its use and the regulatory oversights involved.
Hundreds of women who were exposed to the pregnancy drug DES are calling for a public inquiry, after a year-long ITV News investigation exposed the scale of the medical scandal.
Social Affairs Correspondent @SarahCorkerNews & Senior Producer @LKilraine report pic.twitter.com/7Ey9m3MDjC
— ITV News (@itvnews) November 4, 2025
Victims and Advocacy Groups Demand Action
Victims of DES, often referred to as “DES daughters” and “DES sons,” alongside advocacy groups, are fighting for recognition and compensation. They emphasize the lack of accountability and call the situation a “national scandal” due to the government’s failure to act. These groups are pushing for formal recognition of DES-related health impacts and financial support for affected families.
Despite the ongoing advocacy, as of November 2025, no comprehensive public inquiry has been launched in the UK or Australia, though some countries have begun medical monitoring programs for those exposed to DES.
Implications for Drug Regulation and Public Health
The DES case serves as a cautionary tale for pharmaceutical regulation, highlighting the consequences of limited oversight and the importance of rigorous drug safety standards. The scandal continues to influence legal precedents around drug liability and patient rights, emphasizing the need for informed consent and vigilant pharmacovigilance. As calls for reform grow louder, the case underscores the critical role of regulatory agencies in safeguarding public health.
The push for a public inquiry continues to gain traction, reflecting broader societal concerns around trust in medical and regulatory institutions. As the victims’ advocacy gains momentum, the DES case remains a significant chapter in the ongoing dialogue on drug safety and regulatory responsibility.
Sources:
Diethylstilbestrol: Lessons from the past
Diethylstilbestrol – Wikipedia
DES exposure and cancer risk
Ethical implications of DES
